Terms ending in 2031
Every in-force patent on Phio Pharmaceuticals Corp.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,300,027 | Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition In force · High confidence | Hapten Pharmaceuticals, LLC | In force | High confidence | |
| US 9,340,786 | RNA Interference in Dermal and Fibrotic Indications In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 10,184,124 | RNA Interference in Ocular Indications In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence | |
| US 10,240,149 | Reduced Size Self-Delivering Rnai Compounds In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 10,662,430 | RNA Interference in Ocular Indications In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 10,913,948 | RNA Interference in Dermal and Fibrotic Indications In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 11,118,178 | Reduced Size Self-Delivering Rnai Compounds In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 9,095,504 | RNA Interference in Ocular Indications In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence | |
| US 11,584,933 | RNA Interference in Ocular Indications In force · Medium confidence | Phio Pharmaceuticals Corp. | In force | Medium confidence | |
| US 9,080,171 | Reduced Size Self-Delivering Rnai Compounds In force · High confidence | Phio Pharmaceuticals Corp. | In force | High confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
9 of these are in force and held by Phio Pharmaceuticals Corp..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.